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INTRODUCTION 
 
First described by Jean Berger as a disease entity with diffuse mesangial 
deposition of IgA deposits. Once thought to have benign entity of self limiting 
hematuria, now found to have slowly progressive  in nature with the propensity to 
develope chronic kidney disease in 15-20 percent in 15 -20 years. 
It presents with constellation of clinical syndrome ranging from 
asymptomatic urine abnormalities to smoldering rapidly progressive glomerulo 
nephritis. Diversity of clinical signs and syndrome is a constant feature. 
With the advance in genetic, more molecular pathways are unraveled, 
pathogenesis were defined little better than previous, so this commonest 
glomerulonephritis is revealing its secrets. 
Better understanding of glycation,  galactosylation molecular machineries in 
depth of enzymes and chaperone, better search of happenings  of  talks of  
mesangium, podocytes and proximal tubule through cytokines and receptors, better 
knowledge of mucosa marrow axis and TLR  clearly  will open new prospective in 
treatment. 
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Epidemiological point of view, both increasing awareness such as treatment 
of for hematuria, prompt referral to the nephrologist, more precise 
immunoflourescence  studies, IgA  nephropathy  incidence is on increasing trend . 
Hence   proper, long term randomized  control trials(RCT) needed in many areas of 
IgA nephropathy.  
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AIM OF THE  STUDY 
    
     1. To study the epidemiological profile of IgA nephropathy in adult  
          patients. 
 
     2. To study the clinicopathological correlation of   IgA nephropathy.  
 
     3. To evaluate the response to treatment, predictors of response and  
          Risk factors in the progression to CKD in these patients. 
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REVIEW OF LITERATURE 
The first description of IgA nephropathy dated back in 1968 by Jean Berger1. 
Levy coined the term Berger’s diseasein1973.Now it is the most frequent type of 
glomerulonephritis. Once thought to be benign recurrent hematuria, now an 
important cause for end stage renal disease. It is thought to IgA nephropathy be a 
constellation of clinical entity due to various injurious mechanism.  
Definition of IgA nephropathy: 
       It is a pathological diagnosis needs light microscopy and 
immunoflourescence study of renal biopsy. Study of IgA nephropathy is defined as 
dominant or codominant staining with IgA of at least 1 + in the mesangial area2. 
Epidemiology:  
           IgA nephropathy is recognized as the most common form of primary 
glomerulonephritis   in the world3.   Incidence and prevalence of IgA nephropathy 
in general population shows a considerable variation among geographical regions. 
The reported incidence in three regions in France and one each in the Netherlands, 
Germany and Italy varied from 15 to 40 new cases per million populations per 
year4-8. Japan and Korea had highest recorded incidence . 48 percent of Japanese 
children initially identified through urinary screening program who subsequently 
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underwent a renal biopsy had IgA nephropathy. Fifty percentages of new cases of 
glomerulonephritis in Japan attributed to IgA nephropathy9.  
Available evidence suggests an increasing incidence in India. Indian studies 
showed 8.6% of renal biopsies (Vellore)10, 14% of renal biopsies from Kerala11, 
16% of renal biopsies from western India12. Primary IgA nephropathy occurs at 
any age, most commonly with clinical onset in the second and third decades of life 
Male to female ratio around 1.5 to 1.85:1. 
Genetics: 
IgA Nephropathy mostly seen in Asian cohorts, rare among American  and 
African  blacks, highly prevalent in Zuni  Manitoba  Native Americans  and      
Australian Aborigine, obviates search for genetic association.13-18 Search for 
susceptible loci, modifier gene, environmental trigger was started19. Many genome 
wide studies points towards locus like IGAN1 on chromosome 6q2220, 17 q1221, 
and 2q3622.  Micro RNA mirco148 b were upregulated23. Family history of IgA 
nephropathy was noted in 4-10% in UK24. So IgAN thought to be associated with 
polygenic genes includes both major histocompatability genes and non 
compatability genes. The gene mutation associated with beta 1,3 galactosyl 
transferase enzyme and cosmc were inconclusive25-29 
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Lanthanic IgA deposits 
IgA deposits in mesangium is common in normal healthy individuals. 
(around 1 in 400) but only a few show clinical signs and picture of IgA. So, there 
lies an second hit mechanism either genetics or environmental. 
Pathogenesis: 
Basic structure of IgA: 
IgA first appears in life in eleventh week after birth. IgA exists in two 
form.1.Serum IgA, 2.Mucosal (secretory) IgA. Serum IgA mostly present in 
monomeric (mostly IgA1) form with molecular weight 160000, produced from 
bone marrow. Mucosal IgA present with polymeric form joined by J chain, 
secreted from the mucosal surface. IgA1 accounts for 90% of serum IgA, produced 
in bone marrow, lymph nodes, plasma cells and spleen. IgA2 comprises 60% in 
mucosal areas. J chain produced from the same plasma cells that produce the 
dimeric IgA. This dimeric IgA-J chain complex get internalized from the basal 
layer of mucosa through IgA/RR dimer complex. This dimeric IgA extruded 
through the mucosal apical surface along with J chain and a extracellular part of 
RR IgA poly known as secretory component (SC). 
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                        IgA consists of two sub classes-IgA1, IgA2. 
IgA1 10   O- glycosylation sites 2   N - glycosylation sites 
IgA2 No O- glycosylation sites 2-3 additional    N - glycosylation sites
 
Glycosylation &galactosylation  
IgA1 contains 17 amino acid(AA) hinge region rich in serine, threonine and 
proline31. Three  proline in the hinge region forms the universal joints and forms 
right angle bends.IgA2 devoid of 13 AA in the hinge region , resistive to 
proteolysis by bacteria, hence naturally present in mucosa. These hinge regions by 
addition of O- glycan chains thus undergoes post translation modifications. 
Glycosylation in hinge region (AA 223-240) takes place by addition of N acetyl 
galactosamine (GalNAC).Galactose get incorporated to the Serine or 
Threonine/GalNAC complex by C1GalT1(core1β 1,3 galactosyltransferase 
enzyme.)  These Galactose residue sialylated by α 2,3 sialyltransferase enzyme. 
Addition of sialic acid directly to GalNAC by α2,6 sialyltransferase enzyme32. The 
beta 1, 3 galactosyl transferase enzyme stabilized by Cosmc (core 1 beta 1,3 
galactosyltransferase molecular chaperone) which ensure proper folding.33 
Addition of sialic acid prevents the incorporation of galactose.  So pathogenesis 
mainly resides in under galactosylation  or over sialysation. The immortalized B-
cells of patients with IgA nephropathy  produce galactosylation deficient IgA34 . 
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            Normally IgD produced earlier in life were heavily glycosylated and less 
sialylated than IgA. Serum IgA was heavily glycosylated and sialylated. Mucosal 
IgA was poorly galactosylated. So there is down regulation of galactosylation and 
up regulation of sialyltransferase when there is class switch. In IgA Nephropathy 
IgD galactosylation pattern is not affected implies pathogenesis doesn’t affect the 
entire B cell lineage35   
Two hit model : 
Under galactosylation: 
Pathogenesis includes two hit model. First one is the presence of under  
galactosylated IgA1 O glycoforms in circulation and second one is the formation 
of IgG antibodies to it. Under  galactosylation either by defective  core1 β 1,3 
galactosyltransferase enzyme,its chaperone cosmc or  over sialysation  by α2,6 
sialyltransferase enzyme may elucidate pathogenesis, but genetic studies for 
mutation are inconclusive. 
Ultimatum was the mesangial IgA deposition.Only 15% of deposits 
colocalise with secretory compononent (SC), others were not. So it is of polymeric 
IgA1 with undergalactosylation. Van Es et al suggested impaired mucosal bone 
marrow axis produce nephritogenic IgA.   Due to mucosal infection there is a class 
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switch mediated by Toll like receptor (TLR 4,9)36,IgA+ antibody secreting 
cells(ASC),which homes in systemic sites, produce normal mucosal type IgA 1 
IgG antibodies:  
These poorly galactosylated IgA1 invokes IgG antibodies react with 
neoepitopes. Cross reacting antibody produced molecular mimicry also reacts with 
it.  Polymeric IgA also interacts with FCαR1 (CD 89) receptors on myeloid cells 
breaks to form larger sCD89 isoform (50-70 KDa), results in circulatory immune 
complexes37-39. These immune complexes (IC)  reaches a molecular weight of 800-
900 kDa .  Normal serum IgA had short half life of 6 days  as it  is cleared through 
asialoglycan receptors in liver. As the fenestrae in liver to enter space of disse is 
around 200 A where as in glomerular capillary around 500-1000 A ,these  IC got 
deposited in mesangium than cleared by liver40. 
Mesangial and podocyte injury:  
This immune complexes recognized by transferring receptor (CD71), 
produce proinflammatory and profibrotic cytokines (IL-6,TGF β).  Secretory 
component of IgA, with a high sialic acid content and its anionic property 
stimulates mesangial cells resulting in activation of the  p42/p44 mitogen activated 
protein kinase, activator protein-1, and NF-B signal transduction pathways along 
with up-regulation of IL-6, transforming growth factor-β (TGF-β), tumor necrosis 
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factor (TNF-α), monocyte chemo attractant protein1 (MCP-1), IL-8, and 
macrophage migration inhibitory Factor41-43. 
  By binding of IgA and immune complexes to the podocyte not through 
transferrin receptors but through an unidentified receptors , by loss of nephrin and   
by mesangium podocyte talk  produces glomerulo sclerosis by damaging podocyte. 
            Extracellular matrix production increased. Filtered cytokine incites 
proximal tubular cell activation and through glomerular tubular cross talk mediated 
through angiotensin II, IL6, TNFα. TGFβ mainly through PPAR-γ promotes tubule 
interstitial scarring. IgG antibody to underglycosylated IgA1 are specific for IgA 
nephropathy and correlates with clinical disease. 
                             Thus pathogenesis summarized in 3 steps. IgA deposit in the 
Mesangium; II) generation of the mesangial lesion mediated by the interaction of 
the IgA1 complexes with specific receptors or through the activation of the 
complement, and III) progression of the mesangial IgA lesion towards chronic 
renal failure.  
 
Pathogenesis of  mucosa marrow axis in IgAN  is simplified as 
1. Class switch production of IgA+ antibody secreting cell(ASC) 
2. Mistraffiking to bone marrow 
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3. Monomeric to polymeric IgA 
4. Retaining of poorly galactosylated form 
5. Formation of IgG antibody. 
6. Binding to CD89 in myeloid and its shedding 
7. IgG+ CD89+poorly galactosylated form deposition in Mesangium 
 
Complement in IgAN: 
In 80% cases IgA was co deposited with C3, membrane attack complex. In 
IgA nephropathy, immune complexes activate classical pathway where as 
polymeric IgA activates lectin pathway through recognisation molecules like 
mannose binding lectin, ficolin. Lectin pathway activation had an unfavorable 
progression.Glomerular C3c deposits   parallel with disease severity.44-45  
Animal models:46 
1. Murine antidinitrophenole and dinitro phenole conjugated bovine serum model 
2. Animal immunized with bacterial derived polysaccharide or chemically 
modified dextran.  
 - Both the model confirmed IgA-IC IN mesangial deposition.  
3. Uteroglobulin deficient mouse model;-shows Fibronectin collagen co deposition 
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4. Spantanous IgAN prone mouse(ddY) mouse 
5. Autoimmune prone mouse (NZW×C 57BL/6):- presents with IgA 
hyperglobulinemia 
6. Mice lacking β 1,4 galactosyl transferase 
Clinical features 
Pattern of clinical presentation: 
Common: 
1. Synpharyngitic macroscopic hematuria 
2. Microscopic hematuria 
3. Hypertension 
4. Chronic Kidney Disease 
5. Henoch schonlein Purpura 
Uncommon: 
1. Malignant Hypertension 
2. Acute renal failure 
3 Acute Nephritic Syndrome  
4. Nephrotic syndrome 
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Macroscopic Hematuria:  
Most often present as painless hematuria, in noted around 40% patients. 
Macroscopic hematuria   mostly presented in children and young adults, rare after 
40 years.  It is usually seen 1 to 2 days after the sore throat. It is usually recurrent 
one after each infection. Macroscopic hematuria may present with loin pain. 
Macroscopic hematuria resolves spontaneously in majority of the patients.       
Asymptomatic Hematuria: 
           Around 30 to 40 % of patient presented with asymptomatic hematuria, 
associated with or without proteinuria. It shows an iceberg effect in its prevalence. 
Mostly detected in population screening. 
  Proteinuria and Nephrotic syndrome: 
Proteinuria in the absence of hematuria is an uncommon presentation. 
Nephrotic syndrome is uncommon and seen around 5 percent of patients with IgA   
nephropathy. It may be a manifestation of early disease or advanced stage of 
disease. Though a threshold of 1g/day of proteinuria had a risk of progression but 
seems to be a continuum. 
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 Acute renal Failure: 
           Acute kidney injury (AKI) was seen around 5 percent of patients. AKI 
occurs mainly during the episodes of macroscopic hematuria. Renal biopsy in these 
patients reveals mesangial proliferation and crescents in small proportion of 
glomeruli (25%). Mechanism for causing AKI in these patients may be attributed 
to tubular obstruction by red cell casts. But  most common histological lesion is 
acute tubular necrosis  which is probably induced by the iron released from the 
lysed  red blood cell in the tubule,toxic free oxygen radical generated via the Haber 
–Weiss-Fenton reaction.Crescentric nephropathy(crescent affecting >50% of 
glomeruli)may be an another factor.  
 
 Hypertension and Malignant hypertension: 
Some proportion of patients with IgA nephropathy is detected to have newly 
diagnosed hypertension. In young adults it is one of the major causes of 
hypertension. Malignant Hypertension is the most dramatic presentation in IgA 
nephropathy. Some studies documented up to 5% of accelerated hypertension. 
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Rapidly progressive renal failure: 
It is a manifestation of acute necrotizing glomerulonephritis which warrant 
immunosuppressive therapy. Mostly mimics pauci immune crescentric 
glomerulonephritis, sometime associated with IgA ANCA47.  
 
Chronic Renal Failure; 
Approximately 10 to 20 percent of patients with IgA nephropathy had 
chronic established renal failure at presentation. Mostly tend to be older and with 
long standing disease.  
 
Natural history;  
                     Most studies now addressing natural history of IgA48 .A study from 
France documented 7 year renal survival of 82%49. Twenty five  percent end up 
ESRD in 20 years and another 20% had progressive impairement .According to 
Canadian study  but those who achieved urine protein <0.2 g had  least risk  and 
also better renal survival with urine protein<1g/day.50 But in 7 year follow up study 
of patient with  isolated microscopic hematuria, 44% reached renal impairement51. 
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Histopatological classification: 
There are various classification of IgAN nephropathy. They are  
1. Lee  classification52 
2. Hass  classification53 
3. Churg and sobin classification56 
4. New oxford MEST scoring system57 
As older classification divided as two system, 1.Lumped system 2.split 
system lumped system named for its simplicity, applicability in larger studies 
hence it plays a role in diagnosis and grading. E.g. Lee  et al.   
           Split system looks into the detailed aspects of glomeruli, interstitium, 
vessels and had global score. Hence it is useful in assessing progression of 
disease.Eg. Kobayashi et al54 Waldo et al55 . 
1.  Lee classification: 
Grade1:   
Glomeruli   : normal with or without hypercellularity 
Tubulointerstitium (TI) ; normal 
Grade2:  
Glomeruli   :     <50% of glomeruli show localized mesangial  
      proliferation  with sclerosis 
Tubulointerstitium (TI) ; normal 
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Grade 3: 
Glomeruli   ; diffuse mesangial proliferation, occasional crescents   
Tubulointerstitium (TI) ; focal interstitial edema, rare tubular atrophy                    
Grade4: 
Glomeruli   ; marked diffuse mesangial proliferation and sclerosis 
  Crescents<45% of glomeruli 
Tubulointerstitium (TI) ; tubular atrophy and interstitial inflammation 
 
Mark Hass et al modified Lee et al and added D’Amico et al48 and 
introduced his classification 
 
2 .Mark Hass classification 
Subclass I:    
Minimal histological lesion  
Glomeruli  ;          minimal increase in cellularity 
              No segmental sclerosis or crescents 
Subclass II:     
Focal segmental glomerulosclerosis like 
Glomeruli :  focal segmental sclerosis with slight mesangial  
                                         cellularity ,no crescents  
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Subclass III: 
Focal proliferative GN 
Glomeruli  ; 50% hyper cellular which is either mesangial or  
              Endocapillary   
Subclass IV;           
Diffuse proliferative GN 
Glomeruli  :         >50% hyper cellular which are either segmental or  
              global .Crescents may be present  
Subclass v:  
Advanced   chronic GN                                 
Glomeruli  :  40% of glomeruli are globally sclerotic with 40%  
tubular atrophy. 
 
There is statistically significant between Hass  subclass and renal survival. I, 
II had greatest survival > Ill> IV, V. 
3. Chrug and sobin classification56 
Grade I  : ClassA; normal glomeruli 
                                         Class B: slight mesangial hypercellularity 
                                         Class C: Slight mesangial matrix expansion 
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Grade II :  
Class A : <25% glomeruli with moderate focal segmental  
proliferation. occasional tubular infiltrates. 
Class B :  upto 50% glomerulo with focal and segmental  
                                      proliferation. cellular   crescents <25% of glomeruli.  
                                         Tubular atrophy( TA) and interstitial infiltrate up to 50%  
Class C ; >50% of glomeruli with segmental proliferation   
and  sclerosis. Crescents up to 50%.TA and interstitial 
                                      changes  in 50% cortical area. 
Grade III :   
Class A ; sclerosis <25% of glomeruli, fibrous crescents  
in <25%, Tubular fibrosis  in <25% of cortical area.  
Class B  ; sclerosis up to 50% of glomeruli, fibrous crescent in  
50%, tubular fibrosis and interstitial infiltrate upto 50%  
of cortical area. 
Class C ; sclerosis>50% of glomeruli, fibrous crescents in >50%   
of  Glomeruli. Tubular atrophy and interstitial infiltrate 
>50% of the Cortical area. 
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New oxford MEST scoring 
Daniel C. Cattran, Rosanna Coppo, H. Terence Cook, Ian S.D. Roberts, John 
Feehally  introduce this scoring system by analyzing the biopsies of   265 adults 
and children with IgA nephropathy57  
Four variables were analysed (1) the mesangial hypercellularity, (2) 
segmental glomerulosclerosis, (3) Endocapillary hypercellularity, and (4) tubular 
atrophy/interstitial fibrosis. This  scoring system was validated in a north American 
study58.  
Variable Definition Score 
Mesangial 
hypercellularity 
<4 mesangial cells/mesangial area=0 
4-5 mesangial cells/mesangial area=1 
6-7 mesangial area/mesangial area=2 
>8mesangial area/mesangial area=3 
M<0.5 
M>0.5 
Endocapillary 
hypercellularity 
 Due to increased number of cells in 
lumina to cause narrowing 
E0 –absent 
E1-absent 
Segmental sclerosis Any amount of tuft involving 
sclerosis 
S0-absent 
S1-present 
Tubular 
atrophy/interstitial 
fibrosis. 
 
% of cortical area involved 0 -25%-T1 
25-50-T2 
>50-T3 
 
Advantages of this scoring lies in the high inter observer reproducibility. Its 
weakness lies in the non includes of crescents or necrotizing lesions 
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Treatment strategies; 
Patients were treated according to clinical syndrome. Patient presenting with 
asymptomatic hematuria and proteinuria <500 mg/dl were given only supportive 
care. Those with 500mg to 1 g/day were suggested ACEI. Patients with >1g/day 
ACEI drug is titrated to blood pressure of <125/75 mm of Hg with aim of 
reduction of urine protein of <1g/day. If it is not achieved and GFR is above 
50ml/min then steroids are added. (Dosage: 1mg/kg/day×2 months, tapering of 0.2 
mg/kg over 4 months). Those with nephrotic syndrome were treated as per MCD 
protocol. Those with crescents were treated as per vasculitis protocol (regimen; 
Pulse steroid 7-15 mg/kg×3days followed with oral steroid 1mg/kg/day×4 weeks 
tapered to 20 mg/day in 2 months and  iv cyclophosphamide 15 mg/kg/day every  2 
week ×3 doses ,then every 3 weekly.). 
 In patient present with RPGN, combination of steroid and 
cyclophosphamide as per vasculitis protocol and followed with maintenance 
therapy with azathioprine/MMF if there is response.  
               It is better to renal biopsy if there is no improvement after 5 days in acute 
kidney injury to rule out crescent as  a cause which needs immunosuppressant  
drugs where as ATN  needs only supportive  therapy. 
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Treatment strategy in IgA nephropathy 
Presentation  Treatment  
Hematuria &proteinuria<500mg/dl Supportive treatment 
Urine protein(500 -1000mg/day) ACEI/ARB 
Urine protein>1000 mg ACEI/ARB, target  BP 125/75 mmHg 
Optimal ACEI but urine 
protein>1000mg/day 
And GFR>50 ml/min 
Steroids(1mg/kg/day×2 months and 
tapered to 0.2mg/kg/day over 4 months) 
AKI with gross hematuria 
Renal biopsy if no improvement by 
day5 
ATN-supportive care 
Crescents-treat as below 
IgA with crescents Treat as ANCA vasculitis 
IgA with MCD Steroids as MCD protocol 
IgA with s.creatinine >2.5 mg/dl CKD supportive care 
 
Role of ACEI/ARB 
Praga et al showed renal survival even in patients with high degree of 
proteinuria59. Horita et al showed significant reduction in proteinuria even in 
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patients with crescents.60HKVIN trial in china and IgACE   were underpowered 
enough to comment on role of ACEI. 
 
Role of fish oil; 
By reducing eicosanoid, curtailing cytokines, fish oil had anti inflammatory 
action.  Donadio et al showed in patients with nephrotic range of proteinuria, high 
dose fish oil(12g) significantly reduce proteinuria and  had long term renal survival 
in their 6 years follow up. They also showed better outcome with low dose 
(4g)61.Appel et al documented improvement in low dose treatment also62 .Ferraro 
showed reduction of proteinuria, but RCT was definitely lacking. Considering 
cardiovascular beneficiaries and low risk profile it may be an option. 
 
Role of steroids 
In non proliferative IgA N Pozzi et al showed renal survival. In their study 
of 86 patients, after 6 months of therapy, patients with <1 g proteinuria had better 
renal survival63. Katafuchi et al in 90 patients of steroid for 2 year,long term study 
fails to have better renal survival64.Lai et al  documented the benefits of short 
course of steroid in proliferative IgAN with improvement in GFR.  
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Combination of steroid and cyclophosphamide 
Bellardie et al and Roccatello et al, both the studies showed better renal 
survival in patient treated with combination drugs  compared to control. Bellardie 
et al  showed 5 year survival of 72%65. Roccatello et al showed 5 year survival of 
91% even with crescents treated with  steroid and cyclophosphamide66. No RCT 
available. 
 
Role of MMF 
RCT findings are variable. A Belgian study and North American study 
showed no renal survival and reduction of proteinuria but a Chinese study showed 
significant reduction of proteinuria67-68 
 
Role of tonsillectomy: 
Studies from Japan69-70 showed   better renal survival but European study 
gave negative result71-72. Argument for better survival includes that tonsil by 
homing of mucosal type of B cell, produces poorly galactosylated antibody and 
recurrent tonsillitis provokes hematuria. 
 
Other studies showed that it is not tonsillectomy but combined steroid 
therapy had beneficiaries. Recent study showed that tonsillectomy had survival 
advantages over steroid. But still now there were no proper RCT. 
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Newer drugs and hopes  
 
1. Locally acting budesonide-acting at ileocecal region 
2. TLR agonists 
3. Small molecule inhibitors-of nucleic acid sensing TLR 
4. Hydroxychloroquinine; inhibition of antigen processing and presentation by 
                         i) Inhibitor of TLR9 
                        ii) Alkalinization of  proteosome. 
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MATERIALS AND METHODS 
 
Study design:  Prospective observational study 
Study period:  November 2011-February 2013 
Study centre:   Department   of nephrology, Madras medical college, Chennai 
INCLUSION CRITERIA:  
All patients who have biopsy proven IgA nephropathy under the care of 
department of nephrology,  has been included in the study. 
EXCLUSION CRITERIA: 
1. Liver disease 
2. Skin disease like psoriasis 
3. Malignancy 
4. Human immune deficiency virus 
5. Leprosy  
6. Systemic lupus erythromatosus, rheumatoid arthritis and other  Reactive 
arthritis 
7. Diabetic nephropathy 
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Patients who got admitted under care of our department of nephrology were 
taken of detailed clinical history. Clinical history include, edema, difficulty  of 
breathing, head ache, blurring of vision, reduction of urine output,  hematuria, loin 
pain, fever, and other relevant history are taken. History regarding systemic illness, 
regarding comorbitidies, drug history, and personal history, dietary habits was 
taken. History of cigarette smoking and alcohol intake were probed. Detailed 
clinical examination including blood pressure examination in all 4 limbs and 
complete systemic examination were done. Those with blood pressure >140/90 
were diagnosed to had hypertension. 
    Patients were subjected to routine urinary examination includes urine for 
protein, deposits like red blood cell, white blood cell. Urine was analyzed also red 
blood cell cast, white blood cell cast.  Urine protein/creatinine ratio was done .  
Patients underwent routine hematological investigation like blood hemoglobulin, 
total count, differential count, peripheral smear study. Blood investigation include 
blood urea, serum creatinine, serum electrolyte, lipid profiles were taken. Liver 
function test including serum bilirubin were taken. GFR estimated by Cockcroft 
gualt equation (ml/min) .Urine for culture and sensitivity and blood for culture and 
sensitivity was done.  Ultra sonogram of abdomen, ultra sonogram kidney and   
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urinary tract which includes size of kidney, cortical echogenesity, and whether 
cortical medullary differentiation present or not. Chest x ray PA view and 
electrocardiography were done in appropriate patients. 
           Renal biopsies were done where there is an appropriate indication. 
Indication for renal biopsy includes unexplained renal failure, those presented with 
nephrotic syndrome, those with nephritic syndrome, on subnephrotic proteinuria  
those had an sudden rise in serum creatinine. Bleeding  time(BT) ,clotting 
time(CT),prothrombin time(PT),activated partial thromboplastin time(APTT) were 
done. Those who presented with contracted kidney were not biopsied. Kidney and 
urinary tract were also looked for dilated systems. Blood pressure was recorded. 
Sterility of urine culture was ensured.  Patients were explained in detail about the 
renal biopsy procedure and informed and written consent were obtained. 
            Renal biopsy was done in prone position. Ultra sound was to locate the 
lower pole of kidney and skin marking was done. Under strict aseptic precaution, 
local anesthetic (2% lignocaine) was infiltrated in renal angle area. Under ultra 
sound guidance, using 16 G biopsy needle, renal biopsy was done with the patient 
in deep inspiration. After conforming renal tissues, patients were advised bed rest 
and collection of urine sample. Patient informed to report any increase in 
abdominal pain. 
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             Renal biopsy tissues sent for histopatological examination. These were 
done by light microscopy and immunoflourescence study.  Glomeruli, tubule, 
interstitium and vessel were examined with hematoxylin and eosin, periodic acid 
Schiff and trichrome.  MEST  scoring was done. Immunoflourescence studies for 
IgA.IgM, IgG, C3, C1q were done. Intensity graded from 0 to 4.  Those with 2 + 
and more of dominant or codominant deposit of IgA, diagnosis of IgA nephropathy 
was made. 
After excluding those who met exclusion criteria diagnosis of primary IgA 
nephropathy were made. Patients were treated according to clinical syndrome. 
Patient presententing with asymptomatic hematuria and proteinuria <500 mg/dl   
were given only supportive care. Those with 500mg to 1 g/day were suggested 
ACEI. Patients with >1g/day ACEI drug is titrated to blood pressure of <125/75 
mm of Hg with aim of reduction of urine protein of <1g/day. If it is not achieved 
and GFR is above 50ml/min then steroids are added. (Dosage: 1mg/kg/day×2 
months, tapering of 0.2 mg/kg over 4 months). Those with nephrotic syndrome 
were treated as per MCD protocol. Those with crescents were treated as per 
vasculitis protocol (regimen; Pulse steroid 7-15 mg/kg×3days followed with oral 
steroid 1mg/kg/day×4 weeks tapered to 20 mg/day in 2 months and  iv 
cyclophosphamide 15 mg/kg/day every  2 week ×3 doses ,then every 3 
weekly.).Sterility of urine and blood and chest X ray be must to start 
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immunosuppression. Response to treatment was assessed with improvement of 
renal function and remission of proteinuria (complete remission as urine 
protein<300 mg/day, partial remission as urine protein 300-3000mg/day and  nil 
response  of >3000mg/day). 
           Patients presented with acute kidney injury, if there were no renal 
improvement biopsy attempted at 5th day   to exclude crescents or acute tubular 
necrosis. 
Patients were divided into two cohorts, those had renal failure at 
presentation (GFR<60ml/min) and those had no renal failure at presentation 
(>60ml/min).  Various factors including clinical and biopsy study were analyzed. 
           Patients were on regular follow up. Those who progressed to chronic kidney 
disease [CKD (GFR<60 ml/min)], end stage renal disease [ESRD(GFR<15 
ml/min)] were analyzed with various clinicopathological factors. These patients 
were compared with the patients who never reach CKD and ESRD respectively. 
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RESULTS 
              A total of 92 patients with biopsy proven IgA Nephropathy were included 
in the study. Of which 5 patients who present with end stage renal disease at 
presentation were excluded. Eighty seven patients are finalized into this study.   
Sixty eight (67.8%) patients were male. The follow up period ranged from 6-28 
months.   The mean age at presentation was 27.3years. Majority of patients (35) 
presented in 10-19 years age groups (40.2%),followed by  twenty five patients in 
20-29years age groups (28.8%).  Five patients were in 30-39 years age groups 
(5.7%). Fourteen were in 40-49 age groups (16.1%). Seven were in 50-59 age 
groups (8%) and one was in 60 years. Patients were stratified according to age 
groups as given in table 1. 
 
TABLE:1   
 Table1 
Total number of patient 87 
Male 59(67.8%) 
Female 28(32.2%) 
Mean age 27.3 years 
10-19 years 35(40.2%) 
20-29  years 25(28.8%) 
30-39 years 5(5.7%) 
40-49 years 14 (16.1%)
50-59 years 7 (8%) 
60 years 1(1.1%) 
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Clinical presentation of patients were classified as in table 
2.Macrohematuria was noted in 36(40%) patients. Hypertension prevailed in 40 
(54%) patients. Edema was present in 66(76%) patients. Oliguria was seen in 59 
(67%).  Seven (8%) presented with hypertensive encephalopathy. Nineteen 
(21.8%) had hypertensive retinopathy. 
TABLE: 2; Clinical presentation  
Clinical presentation Number of patients Percentage (%) 
Macrohematuria 36 40 
Edema 66 76 
Oliguria 59 67 
Hypertension 40 54 
Hypertensive encephalopathy 7 8 
Hypertensive retinopathy 19 21.8 
                        
Depending upon clinical syndrome patients were categorized as in table 3. 
Twenty patients had Nephrotic syndrome (22.9%).Nephritic syndrome was noted 
in 11 patients (12.6%). Twelve presented with rapidly progressive renal failure 
33 
 
(13%). Six presented with acute kidney injury (6%). Those who presented with end 
stage renal failure at presentation were excluded from the study.   
TABLE: 3;Clinical syndrome 
Syndrome Number of patients Percentage (%) 
Nephrotic syndrome 20 22.9 
Nephritic syndrome 11 12.6 
Rapidly progressive glomerulonephritis 12 13 
Acute kidney injury 6 6 
Chronic kidney disease 5 5.4(excluded) 
 
               Renal biopsy findings were tabulated as follows in table no 4 .Scoring 
was based on   Oxford MEST. Mesangial score (M0&M1) was seen in 28 and 59 
patients respectively. Endocapillary cellularity (E1) was noted in 44 patients. 
Sclerosis score (S0 &S1) observed in 45and 43 patients respectively. Tubular 
atrophy and interstitial fibrosis score of T1 and T2 was noted in32 and 40 patients 
respectively. Crescents were noted in 16 patients. Vessel wall thickening was 
present in 24 patients. 
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TABLE: 4: Biopsy findings 
Biopsy   findings Number (Percentage (%) 
M0 28(32.1%) 
M1 59(67.9%) 
E0 43(49.4%) 
E1 44(51.6%) 
S0 45(51.7) 
S1 43(49.3%) 
T0 15(17.2%) 
T1 32(36.7%) 
T2 40(46%) 
Crescents 16(18.4%) 
Vascular thickening 24(27.6%) 
 
     
Renal biopsy tissues were also studied with immunoflourescence staining for 
IgA, IgM, IgG, C3and C1q  showed IgA+C3  in 42 patients(48.2%), IgA+C3+IgM 
in 30 patients(34.4%), IgA+C3+IgM+IgG in 14 patients (16.1%),%)and 
IgA+C3+IgM+C1q in 7 patients (8%).Results were given in table 5. 
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TABLE 5: Immunoflourescence (IF) finding 
IF finding Number & Percentage 
IgA  + C3 42(48.2%) 
IgA+C3+IgM 30(34.4%) 
IgA+C3+IgM+IgG 14(16.1%) 
IgA+C3+IgM+C1q 7(8%) 
 
Clinicopathological variable with renal failure at presentation 
Among the 87 patients 59 (67.9%) were presented with renal failure at 
presentation.   Mean age in who presented with renal failure at presentation was 
27.9 years. Male dominated as 42 (59%). Male: female 2.4:1. Hypertension was 
noted in 35 (59%) patients. Macrohematuria occurred in 21 (35.6%).Nephrotic 
range of proteinuria was present in 27 patients (47.8%).  
           Renal biopsy showed mesangial hypercellularity(M1) in 49(83%) 
,mesangial  score(M1)   >0.5 was noted in 34(83%) ,endothelial proliferation(E1)  
was seen in 33(56%), segmental score ( S1) noted in 49%,tubular atrophy 
/interstitial fibrosis score T1 and T2 was noted in  28(46%) and 29(51%) patients  
respectively. Crescents were noted in 12 (20.2%).Vessel wall thickening was noted 
in 22 patients.   Various factors which were studied between those who presented 
with renal failure at presentation (GFR <60ml/min) and those without renal failure 
at presentation were tabulated in table 6. 
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Table 6 : 
Variables 
No renal failure at 
presentation 
N =28 patients 
Renal failure at 
presentation 
N =59 patients 
 
P value 
Mean age 25.5 years 27.9 years Not significant 
Sex (M% :F % ) 61:39 71:29 P=0.33 
Hypertension 43% 59% P=0.1 
Macrohematuria 54% 35% P=0.1727 
PCR>3g 39% 46% P=0.647 
M0 36% 17% 
P=0.001 
M1 64% 83% 
E0 64 44%  
P =0.108 E1 36 56% 
S0 57% 51% 
P =0.358 
S1 43% 49% 
T0 46.4% 3% 
 
P=0.0019 T1 14.3% 46% 
T2 39.3% 51% 
Crescents 14.2% 20.3% P=0.568 
Vascular 
thickening 39.2% 22% P=0.835 
                   
Twenty five patients (28.74%) progressed to chronic kidney disease               
(GFR<60 ml/min) on follow up period. Mean age was 32.6. Male: female was 
64:36. Macrohematuria was presented in 7 patients (28 %).Hypertension persisted 
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in 17 patients (68%). Response to proteinuria was assessed by those achieved 
complete remission (proteinuria<300mg/day), partial remission(proteinuria 300-
3000mg/day) and nil remission(proteinuria>3000mg/day). Ten patients (40%) 
never attained remission.  One attained complete remission. Fourteen patients 
(56%) attained partial remission. Mesangial hypercellularity was noted in 18 
patients (72%). Fifteen presented with endothelial hypercellularity (60%). 
Segmental sclerosis was observed in 17 patients (68%).  Twelve patients (48%) 
showed tubular atrophy and interstitial fibrosis. Crescents were noted in patients 
(28%).  Twenty one patients had GFR<60 ml/min since from presentation. 
 
            Sixty two patients (71.6%) had normal renal function at the end of follow up 
period. Mean age was 28. Macrohematuria was present in 29 (47%).Thirty patients 
had hypertension (48.3%). Twenty eight patients had complete remission (45%). 
Another twenty four attained partial remission (38.7%). Six never attained 
remission. Cresents were noted in 9 patients (14.5%). Thirty eight patient had GFR 
<60 ml/min at their presentation itself.  
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Variables analyzed in those who progressed to CKD were tabulated in table 7 
TABLE 7 
   
 
Variables 
Progressed to 
CKD 
N =25 
Normal renal function 
at the end of follow up 
N=62 
 
P Value 
Mean age 32.6 28 No significance
Sex (M% :F % ) 64;36 60:40 0.62 
Hypertension 68% 43% 0.98 
Macrohematuria 68% 48.3%  
Response to 
proteinuria CR 4% 45% 
 
0.0001 Partial response 56% 38.7% 
No response 40% 9.7% 
M1 72% 66% 0.8 
E1 60% 46.8% 0.344 
S1 68% 40%% 0.031 
T0 4% 32.3%  
0.07 
 
 
T1 46% 43.5% 
T2 46% 25.8% 
crescents 28% 14.5% 0.2192 
GFR<60 ml/min 
at present 84% 61.2% 0.04 
Vessel wall 
thickening 36% 24% 0.29 
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Clinicopathological variables in those reach ESRD  
 
Of the total 87 patients 15(17.24%) needed dialytic support due to end stage 
renal disease. Mean age was 29.4 years. Hematuria was noted in 40%.hypertension 
in 32% .Those who presented with Nephrotic syndrome was 52% and nephritic 
syndrome was 28%.crescents was noted in 24%. Variables analyzed in those 
needed dialytic support are tabulated below in table 8  
 
Table 8 
Variables Patient progressed to ESRD (N=15) 
Mean age 29.4 
Hematuria (%) 40 
Hypertension (%) 32 
Nephrotic syndrome (%) 52 
Nephritic syndrome (%) 28 
Crescents(%) 24 
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Treatment response with Nephrotic syndrome 
Of the 20 patients presented with nephrotic syndrome, all were started with 
ACEI titrated to reduce the BP target of 125/75 mm Hg, Eighteen were started 
with steroids. 
Eleven (55%) had partial remission. Three (20%) had complete remission. 
Six (30%) never attained remission. Three patients who attained complete 
remission retained their renal function. Of the seventeen who had partial and nil 
remission 7 patients progressed to chronic kidney disease. 
TABLE 9 
Response to proteinuria 
Progressed to 
chronic kidney 
disease 
Stable renal 
function 
P =0.5 
Complete remission n=3 Nil 3 
Partial remission n=11 
7 
 10 
Nil remission n=6 
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Treatment response in RPGN and in AKI 
 
Of the twelve patients presented with rapidly proliferative 
glomerulonephritis, nine patients presented with nephrotic range of proteinuria 
with nephritic sediment. Steroid was given in 11 patients and cyclophosphamide 
with steroid was given in 7 patients as per vasculitis protocol .Six patients 
progressed to chronic kidney disease. Other six were not. 
 
           Acute kidney injury was noted in six patients. Four had acute tubular 
necrosis. One had crescent and  another with no discernible findings  
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Survival probability in response to GFR at presentation 
Survival probability curve by Kaplan Meyer curve shows that those who had 
renal failure at presentation had progressed to end stage renal disease than those 
who had not renal failure. 
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Survival probability in response to proteinuria; 
This Kaplan Mayer curve shows that those who attained no remission went 
to end stage renal disease more probable than who attained partial or complete 
response. 
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DISCUSSION 
Of the 87 biopsy proven IgA Nephropathy, 68 patients were male. Male: 
Female ratio in our study was 2.1:1 which was comparable to Chaco et al10,   with   
M: F ratio 1.85:1.  Mean age  at presentation in our study was 27.3 years compared 
to Neha mittal et al, had mean age of 29.9 years73, and Muthukumar et al74 showed 
mean age of 25.7 years but a decade younger than that quoted in western world. On 
age wise distribution 35 patients (40.2%) were in 10-19 years , in age group 20-25 
years 25(28.8%),in 30-39 age groups 5(5.7%),in 40-49 years 14(16.1%),in 50-59 
years 7(8%) and in 60 years there was one patient. 
Clinical symptoms 
Thirty six (40%) patients presented with macrohematuria in our study.  
Chandrika et al, documented 49.3% had macrohematuria. Macrohematuria was 
presented in 25% of patients with primary IgA Nephropathy from university 
hospital St.Eetinne.  Hypertension was noted in 40 patients (54%), which was 
comparable to Chaco et al,(58%). Seven patients (8%) had Hypertensive 
encephalopathy. Nineteen patients (12.8%) had hypertensive retinopathy.  
Muthukumar et al, documented 21.4% had malignant hypertension. In our 
study macrohematuria was noted in 20 (40%), Hematuria (macro and micro) thus 
observed in 56 (64%) patients. Chako et al showed 69% had hematuria. 
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Clinical syndrome 
Nephrotic syndrome documented around 3% in western studies. Chako et al 
documented 55% had Nephrotic syndrome. Chandrika11 et al, documented 
36.7%.Muthukumar 74et al, documented 25.5% had nephrotic syndrome. Neha 
mittal et al73   study showed 23.1% had Nephrotic syndrome. In our study 22.9% 
had nephrotic syndrome. Rapidly progressive glomerulonephritis (RPGN) was 
noted in 13% patients. Muthukumar et al documented 21% had RPGN.Acute 
kidney injury was present in 6% patients compared to Muthukumar et al (4.1%).        
Mean serum creatinine was 2.03 mg/dl in our study compared to Chako10 et al, 
with  2.3 mg/dl. Comparison of clinical presentation and syndrome with other 
studies are tabulated below.  
Table 8 
 Chandrika et al 
Chako    
et al 
Neha 
mittal    
et al 
Muthukumar 
et al 
Present 
study 
Mean age years 30 32 29.9 25.7 27.3 
M ;F 1.5;1 1.85:1 3;1 2:1 2.1:1 
Mean serum 
creatinine 2.2 2.3 3.1 - 2.03 
Hematuria (%) 49.3 69 78.8 54.9 64 
Hypertension 
(%) 49 69 81 30 54 
Nephrotic 
syndrome(%) 36.7 55 23.1 25.5 22.9 
RPGN(%) - - - 21.4 13 
AKI(%) 11 - - 4.1 6 
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Biopsy findings   
Renal biopsy results of the 87 patients revealed mesangial hypercellularity 
(M score >0.5) in 67.9%. Endocapillary proliferation was noted in 51.6%.  
Sclerosis score (S1) was noted in 49.3%.Tubular atrophy/interstitial fibrosis score 
(T1&T2) was36.7%&46% respectively in our study. Arterial score was around 
24%. 
Daniel C.Cattran showed mesangial score >0.5 as 66%, Endocapillary 
proliferation in 42%, sclerosis score (S1) in 76%, tubular atrophy/interstitial 
fibrosis score(T1&T2) 88% and crescents 42%.arterial score present around 40%57. 
     Neha mittal et al, showed mesangial hypercellularity (M score >0.5) in 
68.18%, endocapillary hypercellularity in 24.4%, sclerosis score (S1) in 48.6%,T1 
score in 30.3% and T2 in 43.93%. Crescents were present in 56%.In our study 
crescents were noted in 18.4%, which was to Chandrika et al (12.3%).73 
          Hamid Naseri et al, showed M1 score in 90.2%, Endocapillary proliferation 
in (E1) 32%, sclerosis score (S1) in 62%, tubular atrophy/interstitial fibrosis score 
in (T1&T2) 30% and 50% respectively75 
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MEST scoring in various studies 
 Cattran   et al 
Neha 
mittal 
Hamid 
Naseri Our study
Mesangial score >0.5 66% 68.18% 90.2% 67.9% 
Endocapillary score (E1) 42% 24.4% 32% 51.6% 
Sclerosis score (S1) 76% 48.6% 62% 49.3% 
Tubular atrophy/interstitial 
fibrosis score in (T1&T2) 88% 73.96% 80% 82.7% 
 
Immunoflourescence study 
Immunoflourescence study of renal biopsy tissue in our study showed 
IgA+C3 present in 42 patients(48.2%), IgA+C3+IgM in 30 patients(34.4%), 
IgA+C3+IgM+IgG in 14 patients (16.1%),%)and IgA+C3+IgM+C1q in 7 patients 
(8%).Chandrika et al showed IgA+C3 present in 105 patients(46.25%), 
IgA+C3+IgM in 80 patients(35.24%), IgA+C3+IgM+IgG in 20patients (8.82%), 
and IgA+C3+IgM+C1q in 5 patients (2.20%)11.In their study full house pattern was 
noted in 4 patients (1.76%),but not in our study. 
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Clinical presentation of renal failure at presentation(diagnosis) 
In our study renal failure at presentation (GFR <60 ml/min) was noted in 
59.4 patients (67.9%).Muthukumar et al showed 61% had renal failure at 
diagnosis. 
The mean age was 27.9 years in who presented with renal failure at 
diagnosis. Seventy one (81.6%) patients were male, which was comparable to 
Muthukumar et al,(70%.) 
          Hypertension was noted in 35 (59%) patients in our study who presented 
with renal failure at presentation. Macrohematuria was noted in 21(35.6%), 
nephrotic  range of proteinuria was present in 27(46%). 
Biopsy finding in renal failure at presentation 
Of the 59 patients who presented with renal failure at presentation, 83% had 
mesangial score (M>0.5),44% had endocapillary proliferation,49% had sclerosis 
score (S1 ).Tubular atrophy/interstitial fibrosis score(T1&T2) was noted in 47% 
and 51% respectively. Crescents were noted in 27% of the above cohort. 
Muthukumar et al showed hypertension in 28.3%, proteinuria >3g/day in 41.7%, 
interstitial fibrosis in 90%, Crescents in 16.7%. 
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Statistical analysis; 
                     Statistical analysis was done by bivariate analysis using chi-square for 
fisher’s exact test, multivariate analysis done by multiple regressions. Male sex, 
mean age both had no significant correlation in those with renal failure at 
presentation. Hypertension, Macrohematuria, proteinuria >3g/day were had no 
significant correlation in this cohort. Mesangial hypercellularity (M score >0.5), 
segmental score (S1), tubular atrophy/interstitial fibrosis score (T1&T2),were 
significantly associated with  renal failure at presentation.  
Daniel C.Cattran et al showed there was significant correlation between for 
mesangial hypercellularity score (M1),endocapillary proliferation score, tubular 
atrophy/interstitial fibrosis score (T1&T2) with reduction in glomerular filtration 
rate .They also showed that there is a significant correlation between mesangial 
hypercellularity score (M1),endocapillary proliferation score, tubular 
atrophy/interstitial fibrosis score (T1&T2) with blood pressure.  
           In our study by multiple regression analysis there is a significant correlation 
between mesangial hypercellularity score (M1), endocapillary proliferation score, 
segmental sclerosis, tubular atrophy/interstitial fibrosis score (T1&T2) with blood 
pressure ( P=0.029) .Crescents had no significant statistical association. There is no 
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statistical association between vessel wall thickening and those with renal failure at 
presentation. 
Muthukumar et al showed that there were no significant correlation between 
male, hypertension, macrohematuria, proteinuria >3g/day in those who presented 
with renal failure at presentation. They showed interstitial fibrosis and vessel wall 
thickening were associated with renal failure at presentation. By multivariate 
analysis they showed only interstitial fibrosis was associated with renal failure at 
presentation, but not vessel wall thickening. 
Variables analyzed for those presented with renal failure at diagnosis are 
tabulated below in table 9 
TABLE 9: 
Variables Muthukumar et al Our study 
Mean age(years) 25.7 27.9 
Sex (M:F) 2:1 2.1:1 
Hypertension(%) 28.3 59 
Hematuria(%) 21.7 35 
Proteinuria >3g/day 41.7 46 
Interstitial fibrosis(%) 90 51 
Vessel wall thickening(%) 56 22 
Crescents(%) 16.7 27 
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Treatment response in nephrotic syndrome;                      
In our study 20% presented with nephrotic syndrome, all of them are started 
with ACE inhibitors and BP was titrated to 120/75 mmHg. Steroid was started in 
16 of them, three (15%) patients attained complete remission, 11(55%) patients 
had partial remission, and six (30%) patients had no remission. Of the 3 patients 
who attained complete remission none progressed to renal failure. Seventeen 
patients with partial and nil remission, 7 of them progressed to renal failure, 10 
were not, but statistically not significant (P=0.54). Reich et al, showed those who 
had sustained proteinuria >3g/day had 25 fold faster decline in renal function. 
          By multivariate analysis those with nephrotic syndrome who progressed to 
renal failure there was significant correlation between mesangial hypercellularity 
score (M1),endocapillary proliferation score(E1),segmental sclerosis(S1), tubular 
atrophy/interstitial fibrosis score (T1&T2) (P=0.001).By univariate analysis 
endocapillary proliferation score(E1),segmental sclerosis(S1) had correlation 
(P=0.04) .  
Treatment response in RPGN                               
Twelve (13%) patients presented with RPGN of whom 9 presented with 
nephrotic range of proteinuria with nephritic sediment. Steroid was given in 11 
patients and cyclophosphamide with steroid was given in 7 patients as per 
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vasculitis protocol . Half of them progressed to chronic kidney disease, half were 
not.  
Treatment of Acute kidney injury  
Acute kidney injury (AKI) was noted in six patients. Four had acute tubular 
necrosis. One had crescent and another with no discernible findings. Two need 
dialytic support, one  need immunosuppressive therapy  with cyclophosphamide. 
Clinical variables in progression of CKD cohort 
In our study during follow up period twenty five patients (28.74%) 
progressed to chronic kidney disease. Mean age was 32.6years. Twenty eight 
percentages of them had macrohematuria. Hypertension persisted in 17 (68%) 
patients. There is no statistical significance noted for hypertension and 
macrohematuria. Those progressed to CKD 10 patients had proteinuria >3g/day 
(nil remission), 14 patients had proteinuria in the range of 0.3-3g/day (partial 
remission), 1 patient had urinary protein of <0.3g/day. There was statistical 
significance noted for who had no response to reduction in proteinuria with that 
progressed to CKD. 
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Analysis of biopsy findings in progressor of CKD  
            There was no statistical significance noted for mesangial score (M1) in 72% 
and Endocapillary proliferation 60% of patients in those who progressed to chronic 
kidney disease. Segmental score (S1) was noted in 68% who progressed to chronic 
kidney disease, which was statistically significant. Tubular atrophy/interstitial 
fibrosis score (T1&T2) was noted in 46% of each who had progressed to chronic 
kidney disease, which was not statistically significant. Twenty eight percentages 
had crescents which was not statistically significant. There is no statistical 
association between vascular wall thickening and chronic kidney disease 
progression. 
Clinicopathological variable in patients not progressed to CKD  
Sixty two patients (71.6%) had normal renal function at the end of follow up 
period. Mean age was 28. Macrohematuria was present in 29 (47%).Thirty patients 
had hypertension (48.3%).Twenty eight patients had complete 
remission(45%),another twenty four attained partial remission(38.7%).Six never 
attained remission. Crescents were noted in 9 patients (14.5%). Thirty eight patient 
had GFR <60 ml/min at their presentation itself.  
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Clinicopathological variable in those who  reach ESRD 
Of the total 87 patients 15(17.24%) needed dialytic support due to end stage 
renal disease. Mean age was 29.4 years. Six patient (40%) associated with 
hematuria.  8 patient had sustained hypertension ( 32% ).Those  who presented 
with nephrotic syndrome was 52% and nephritic syndrome was 28%.crescents 
were noted in 24%.By multiple regression analysis there is a significant association 
between hypertension, mesangial hypercellularity score (M1), endocapillary 
proliferation score(E1),segmental sclerosis(S1), tubular atrophy/interstitial fibrosis 
score (T1&T2), presence of nephrotic syndrome and response to proteinuria  with 
end stage renal disease   warranted   dialytic support( P<0.001).Of which T score 
and those respond to proteinuria(as complete remission <300mg/day, partial 
remission 300-3000mg/day, nil remission >3000 mg/dl)  had better 
significance(P=0.1 and 0.0002 respectively). 
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SUMMARY 
1. Mean age at presentation was 27.3 years. 
2. Nephrotic syndrome was present in 22.9% 
3. Renal failure at diagnosis was 59.4% 
4. There was significant correlation with mesangial score (M >0.5), segmental 
score (S1), tubular atrophy/interstitial fibrosis score (T1&T2) with renal 
failure at presentation  
5. Treatment response to proteinuria had statistical correlation with those 
progressed to chronic kidney disease. Patients achieved nil remission 
significantly progressed to chronic kidney disease. 
6. Of the MEST scoring, segmental score (S1) had significant correlation with 
the progression of chronic kidney disease.  
7. Crescents were not significantly associated with either renal failure at 
diagnosis of IgA nephropathy or with progression of chronic kidney disease. 
8. T score and nil response to proteinuria had statistically significance of 
developing of end stage renal disease. 
  
56 
 
                               
CONCLUSION 
 
1. Nephrotic syndrome is the most common clinical presentation in IgA 
nephropathy. 
2. Majority of the patients presented with renal failure at entry into study. 
3. Severe MEST scoring was significantly associated with renal failure at 
presentation. 
4. Non- responders of proteinuria and those who had severe S and T scores in 
MEST scoring system progressed to chronic kidney disease. 
5. Those who had either complete or partial remission of proteinuria had less 
chance to progression of CKD during the follow up period.   
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18 SATHIANARAYANAN M 52 P A P P P(170/110) F 4.28 3+ 6-8 RBC 11 gm/dl 4.28 68 4.8mg/d 17.2 7.4mg/dl yes
24 SATIYA F 42 P A A A N(120/80) N 6.56 4+ 8-10 RBC 7.7 6.56 80 1.8 17.8 8.2 yes
18 SRINIVASAN M 56 A P P P P(140/90 N 4 4+ NIL 11.2 4 78 1.4 60 5.7 yes
27 MANJULA F 51 A A P A N N 7.8 3+ NIL 9.8 7.8 68 2.1 16.9 5.9 yes
42 VIJAYKARUNAGARANM 42 P A P A P(180/100) E 6.8 3+ NIL 10.8 6.8 86 8.1 9 7.8 yes
18 INDIRAN M 62 A P P A N N 4.5 3+ plenty 10.6 4.5 46 1.1 94.1 4.2 yes
40 BAHRINUSHA F 46 A P P P P(170/120 E 5.6 3+ plenty 9.8 5.6 50 2 16.8 6.1 yes
12 THRILOKCHANDAR M 51 P A P P P(180/100) F 4.8 3+ 8-10 RBC 11.8 4.8 64 1 28.2 4.8 yes
16 UMA F 14 A A P A N(110/80) N 1.4 1+ plenty 9 1.4 16 1.1 48.4 4.8 NO
20 SUMATHY F 44 A P A A N(120/80) N 1.1 1+ plenty 12 1.1 56 1 70 4 NO
16 SUCHITRA F 56 A P P A P140/100 N 0.2 NIL plenty 9.8 0.2 52 1.6 21.9 4.1 NO
41 PARAMASIVAM M 64 A P P P P190/100 N 4.2 3+ 10-12 RBC 6.8 4.2 126 4.8 24 6.8 NO
15 TAMILARASAN M 61 A A A P P(160/100) F 2.6 2+ NIL 10 2.6 98 1.6 70 5.2 NO
46 KARPAGAM M 56 A P A A N N 2 2+ plenty 9.2 2 60 2 14 4.5 NO
16 JYOTHI F 17 A P A A N N 1.15 1+ plenty 12 1.15 46 0.9 96 4 NO
17 ANNAVEL M 47 A A P A N N 0.51 1+ NIL 12.8 0.51 40 1.2 96 4.6 NO
28 PADMAVATHY M 42 A P P P P160/100 F 1.81 2+ plenty 12 1.81 46 1.2 96 4.8 NO
20 BHARATHI M A P A A N N 1.5 1+ plenty 10 1.5 40 1.5 90 1.8 NO
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19 RAJU M 52 A A P P P(160/100) N 0.02 NIL NIL 11.6 0.02 12 1.8 51.5 1.8 NO
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18 SURESH M 58 A A A P N(110/70) N 4.7 4+ NIL 7.8 4.7 42 1.7 70.2 6 yes
40 BANNISHA F 64 A A P P P(170/110) F 5.6 4+ NIL 10.8 5.6 62 1.5 50.6 6.8 yes
21 SANGEETHA F 58 P A P P P(180/100) F 4.5 4+ 10-12 RBC 11 4.5 40 1.2 15.5 7 yes
29 SATHYAMOORTHY M 58 A A A P P(180/100) E 7.9 4+ NIL 12 7.9 112 1.1 68.6 4.6 yes
18 NANDINI F 40 P P P P P(170/120) F 4.8 3+ 10-15 RBC 10 4.8 48 2.2 90.6 6.2 yes
20 ABIRAMI F 44 A A A A P(140/90) N 4.6 4+ NIL 9 4.6 80 1.4 64 1.8 yes
15 KANNIAPPAN M 56 A A P P P(200/100) E,F 5.5 4+ NIL 9.6 5.5 82 2.9 40 6.5 yes
17 SIVAPOOSHNAM M 42 A P P A N N 5.26 4+ plenty 10 5.26 60 1.1 92 4.8 yes
46 PRABAKARAN M 62 A A P P P190/100 F IV, 4.2 4+ NO 8.8 4.2 68 1.2 27.5 7.2 yes
46 RAJESWARI F 62 A A P P P(200/100) E 6.6 4+ NIL 8.5 6.6 108 4.8 19.1 5.8 yes
21 POORNIA F 41 P A P A N N 5.2 4+ 8-10 RBC 12.2 5.2 62 1.6 74.9 4.8 yes
28 KARTHIKEYAN M 51 A A P P N N 4.8 1+ NIL 10.8 4.8 82 2.1 45 1.8 yes
41 KUMAR M 52 A A A P N N 5.28 3+ NIL 11.2 5.28 64 2.47 40 5.2 yes
29 SHANTHI F 42 A A P P N N 5.2 4+ NIL 9.6 5.2 52 5.2 14 4.6 yes
21 UMA F 21 A A A A N N 2 1+ NIL 12.2 2 46 1.1 90 4.4 yes
39 SATIYAMOORTY M 52 P A P P P(180/100) F 1.8 1+ 10-12 RBC 10 1.8 64 2.2 40 6.2 yes
10 USHADEVI F 41 A A P P N N 4.18 3+ NIL 10.4 4.18 26 1 74 1.9 yes
19 RAM M 50 A P P P N N 6.24 4+ plenty 12.8 6.24 16 2.8 18.8 4.1 yes
27 SURESH KUMAR M 42 A A P P P(150/90) N 5.16 4+ NIL 8.4 5.16 62 1.9 50 5.2 yes
20 KRISHNARAJ M 40 P P P P N N 8.5 4+ plenty 8.4 8.5 114 1.2 10 8.2 yes
28 MANOHARI F 46 P P P P N N 7.8 4+ plenty 9.6 7.8 87 2.1 40 6.5 yes
45 VANAJA F 52 P A A P P(140/96) N 4.2 3+ 10-12RBC10.4 10.4 4.2 56 1.49 24.8 5.6 yes
41 CHINNHAMBI M 41 A A P P N N 1.25 2+ NIL 15.6 1.25 26.4 1.1 76 4.1 yes
17 MANIKANDAN M 11 A P A P N N 1.16 2+ plenty 15 1.16 51.4 5.2 18 4.7 yes
27 KANNAN M 52 A A A A P F 4.19 3+ NIL 9.2 4.19 100.8 1.15 26 6.7 yes
18 ILANGOVAN M 56 A P P P P N 2.42 2+ plenty 11 2.42 41 4.6 18 5.1 yes
16 SUBRAMANI M 17 A A P P N N 1.92 1+ NIL 12.8 1.92 79 2.1 28 4.5 yes
21 GANSEH BABU M 41 P P P P P(170/100) F 5.1 4+ plenty 10 5.1 61 5.1 16 8.1 yes
51 CHANDRASEKARAN M 61 A A A A N(110/80) N 1.1 4+ NIL 12 1.1 42 2.72 28.6 7.2 NO
24 MUNIAMMAL F 46 A P P P N(110/70) N 2.6 1+ plenty 9.2 2.6 54 2.27 27.8 7 NO
38 SYED M 62 A A P A P(160/100) F 1.8 2+ NIL 12 1.8 22 1.2 58.1 4.6 NO
12 RAMAN M 52 P A A A N N 2.4 4+ 6-8 RBC 11.8 2.4 48 1.2 19.1 4.4 NO
10 GOVINARAJ M 60 P N A A P(200/110 E 2.8 2+ 10-15 RBC 10.8 2.8 64 2 40.2 5.8 NO
50 GOWRI M 68 A P P A P(180/100) E 0.4 2+ NIL 9.8 0.4 42 0.9 94 4 NO
14 SASIKALA F 52 A P P A P(140/100) N 1.6 2+ plenty 8.8 1.6 18 0.8 90 4.8 NO
18 KRISHNAMOORTHY M 62 A A P P P(140/100) N 2.6 1+ NIL 9.8 2.6 60 2.6 42 4.7 NO
39 VIJAYA F 55 A A P A P140/100 N 1.4 4+ NIL 12 1.4 46 1.8 40 5.6 NO
14 MYSORE RAHMAN M 61 A A P P P(210/110 E 2.7 1+ NIL 8.4 2.7 64 4.8 26 6.2 NO
54 JEGANATHAN M 62 P A P P N N 2.6 2+ 8-10 RBC 11 2.6 16 1 94 4 NO
18 RAVI M 52 P A P P P(180/100) F 2.4 2+ 10-12 RBC 10.8 2.4 40 1 24 6.2 NO
11 MUTHUKUMAR M 55 A A P P P(150/100) F,E 2.4 2+ NIL 12 2.4 46 1.8 70 4.2 NO
39 POONGOTHAI F 56 A A P P N N 0.06 NIL NO 10.8 0.06 42 2.1 67 4.1 NO
21 ARCHANA F 16 P A P P N N 2.2 2+ 15-20RBC 12.8 2.2 56 1.72 41 4.6 NO
38 RAJESH M 56 A P P A N N 0.04 NIL plenty 12.8 0.04 48 2.1 47 4.1 NO
42 KAILAINATHAN M 42 A P P P P(160/90) N 0.06 NIL plenty 10.2 0.06 44 2.8 26 4 NO
17 NANDAKUMAR M 12 A P P P N N 2.4 2+ plenty 10.6 2.4 41.2 2.1 25 4.7 NO
24 THIRUMALAI M 18 A P P P P(140/96) N 1.8 2+ plenty 12.8 1.8 54 1.1 42 5.6 NO
11 KAMATCHI F 47 A A P P P(190/110) F 1.71 2+ NIL 10.2 1.71 56 2.1 52 5.7 NO
45 RAMAMOORTHY M 50 A A P P P(160/100 F 1.2 1+ NIL 9.8 1.2 24 2.8 16 5.6 NO
54 IBRAHIMN M 54 A P P P P(160/90) N 1.8 1+ plenty 12.8 1.8 64 1.2 90 4.7 NO
14 GOPINATH M 61 A P P P P(180/106) F 1.8 2+ plenty 11.2 1.8 68 1.4 101 4 NO
54 PALANI M 17 P A P P P(164/90) F 1 1+ 6-8RBC 10.2 1 58 2.8 17.15 1.8 NO
20 SURYA M 16 A P P A N N 0.02 NIL plenty 12.4 0.02 64 1.6 26 4.2 NO
42 ELUMALAI M 56 A A P P P140/100 N 2.8 2+ NIL 10.4 2.8 47 1.4 46 6.9 NO
56 MARIAMMAL F 50 A P P P N N 2.76 2+ plenty 11.8 2.76 62 1.8 90 5.7 NO
18 RENUGA M 16 A A P P N N 2.4 2+ NIL 11.8 2.4 98 2.1 40 4.7 NO
52 MOORTY M 62 A P P P P F 0.02 NIL plenty 12.8 0.02 67 1.1 44 5.1 NO
41 SENTHIL M 49 A P P P P N 2.6 2+ plenty 10.4 2.6 54 2.1 41.7 6.7 NO
14 JEYAVEL M 56 A P P P P N 2.8 1+ plenty 11.8 2.8 62 2.1 40 6.1 NO
16 SULOCHANA F 51 P A P P P N 1.8 2+ 8-10 RBC 11.6 1.8 57 2.6 40.6 4.5 NO
60 VELAYUTHAM M 62 A P P P N N 2.6 2+ 12-14 RBC 14.2 2.6 78 2.1 17 1.6 NO
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NO yes yes NO YES No 1+ 4+ NO NO 1+ M1 E0 S1 T1 NO GIVEN 4.8mg 1 NO YES 1.4 NIL 1.7 41.1
NO yes yes NO No No No 1+ NO NO NIL M1 E0 S0 T1 YES(1/6) GIVEN 1.8 1 GIVEN No 5.5 NIL 5.22 5.6
NO NO NO NO YES NO 2+ 1+ NO NO 2+ M0 E0 S1 T2 NO GIVEN 1.4 2 NO YES 0.8 NIL 0.8 99.2
NO NO NO NO NO NO 1+ 4+ 1+ NO NO M1 E1 S1 T1 NO GIVEN 2.1 2 NO NO 2.47 NIL 1.4 50.5
NO NO NO NO YES NO 1+ 4+ 1+ NO NO M1 E1 S0 T2 NO GIVEN 8.1 1 MMF  YES 4.2 NIL 6.8 9.5
NO yes yes YES No No 1+ 4+ NO NO NO M0 E1 S0 T2 NO GIVEN 1.1 1 NO No 0.06 2-4 RBC 0.7 114
NO yes yes NO YES No No 4+ NO NO 1+ M1 E1 S1 T2 PARTIAL GIVEN 2 1 GIVEN YES 2.6 2-4RBC 1 64
NO yes yes NO YES No No 4+ NO NO 1+ M0 E0 S1 T1 YES4/10 GIVEN 1 1 GIVEN YES 4.4 NIL 1.6 47.8
YES YES NO NO No No No 4+ 1+ NO 1+ M1 E0 S0 T2 NO GIVEN 1.1 2 NO No 0.4 NIL 0.7 124
YES yes yes NO No No 1+ 4+ NO NO 1+ M0 E1 S0 T0 NO GIVEN 1 2 NO No 0.8 NIL 0.8 80
NO yes NO YES YES NO No 1+ NO NO NIL M1 E0 S0 T0 NO NO 1.6 2 NO No 0.2 NIL 0.7 98
NO yes YES NO YES NO 2+ 1+ NO NO 2+ M1 E0 S0 T2 YES10/14 GIVEN 4.8 1 NO No 4 2.8 10.8
YES NO NO NO YES NO 1+ 4+ NO NO NO M0 E1 S1 T2 NO GIVEN 1.6 2 NO No 0.8 NIL 0.9 101.7
YES yes NO NO No No No 1+ 1+ NO NO M1 E1 S0 T2 PARTIAL GIVEN 2 1 NO No 0.02 NIL 0.6 121
YES Yes NO NO No No No 1+ NO NO NO M0 E1 S0 T2 NO NO 0.9 2 NO No 0.1 NIL 0.7 75
YES NO NO NO No No No 1+ 1+ NO NO M0 E1 S0 T1 NO GIVEN 1.2 2 NO No 0.04 NIL 0.8 84
YES yes NO NO YES No No 1+ NO NO NO M1 E1 S1 T0 NO GIVEN 1.2 2 NO No 0.29 NIL 0.8 82
YES NO NO NO No No 2+ 4+ 1+ NO 1+ M0 E0 S1 T0 NO GIVEN 1.5 2 NO No 0.1 NIL 0.9 74
YES yes NO NO No No No 1+ NO NO 1+ M1 E0 S0 T2 NO GIVEN 1.2 2 NO No 0.2 NIL 0.8 92.6
NO yes NO NO No No No 4+ NO NO NO M1 E1 S0 T2 YES4/11 NO 2.8 1 NO No 0.02 2-4RBC 0.8 92.1
YES yes NO NO NO NO 1+ 4+ NO NO 1+ M1 E0 S1 T0 NO GIVEN 1.1 2 NO No 0.9 NIL 0.6 120.8
NO NO NO NO NO NO 1+ 4+ NO NO 1+ M1 E0 S0 T1 NO GIVEN 1.8 2 NO No 0.2 NIL 0.8 86
NO NO NO YES YES No No 1+ NO NO NO M1 E0 S0 T2 NO NO 1.2 2 NO No NIL NIL 1 79
YES NO NO NO NO NO NO 1+ NO NO 2+ M1 E0 S1 T1 YES(4/15 GIVEN 1.1 1 NO No 0.21 NIL 0.9 81.2
NO yes yes NO No No No 4+ NO NO NIL M0 E0 S0 T0 YES(4/10) GIVEN 1.4 1 GIVEN No 1.2 NIL 0.7 65
NO NO NO NO YES No 2+ 4+ NO NO 1+ M0 E1 S0 T1 YES(4/9) GIVEN 2.56 1 NO No 0.6 NIL 1.29 65
NO NO NO NO NO NO No 1+ NO NO NIL M1 E1 S0 T2 YES(2/6) GIVEN 1.7 1 NO No 1.8 NIL 1.5 21.5
NO NO NO NO YES No No 1+ NO NO 2+ M1 E1 S1 T1 YES(6/25) GIVEN 1.5 1 NO No 4.1 NIL 1.2 61
NO YES YES NO YES No 1+ 1+ 1+ 1+ 2+ M0 E1 S0 T1 YES(1/10) GIVEN 1.2 1 NO No 0.4 NIL 1 94.1
NO NO NO NO YES No 1+ 1+ 2+ NO NO M1 E1 S1 T2 NO GIVEN 1.1 1 NO No 4.2 NIL 0.8 111.8
NO YES YES NO YES NO No 4+ NO 1+ NO M0 E0 S1 T2 YES(1/12) GIVEN 2.2 1 NO No 2.2 5-8RBC 5.8 11.5
NO NO NO NO NO NO 2+ 4+ NO NO 1+ M1 E1 S1 T0 YES(1/8) GIVEN 1.4 1 MMF No 0.56 NIL 0.8 91.7
NO NO NO NO YES NO NO 1+ 1+ NO 1+ M1 E1 S0 T2 NO GIVEN 2.9 1 NO No 1.8 NIL 4.2 19.4
NO yes yes NO No No No 4+ 1+ NO 1+ M1 E1 S1 T0 YES1/21 GIVEN 1.1 1 NO No 0.86 NIL 1 62
NO NO NO NO YES No 2+ 4+ 2+ NO 1+ M1 E0 S1 T1 NO GIVEN 1.2 1 NO No 9.6 NIL 12 12
NO NO NO NO YES No 1+ 1+ 2+ NO 1+ M0 E0 S1 T1 NO GIVEN 4.8 1 NO No 2 NIL 7.2 9.8
NO yes yes NO No No 1+ 4+ 1+ NO NO M0 E1 S1 T2 NO GIVEN 1.6 1 NO No 0.08 NIL 1 70
NO NO NO NO No No No 1+ 1+ NO NO M1 E1 S0 T1 NO GIVEN 2.1 1 NO No 1.4 NIL 1.2 68.7
NO NO NO NO No NO 2+ 1+ NO NO 2+ M1 E1 S1 T2 NO GIVEN 2.47 2 NO No 1.61 NIL 2.6 28
NO NO NO NO NO NO NO 1+ 1+ NO NO M1 E1 S0 T1 NO GIVEN 5.2 1 GIVEN O No 0.2 NIL 0.8 68.8
NO NO NO NO NO NO NO 4+ NO NO NO M1 E1 S1 T2 NO GIVEN 1.1 2 NO No 0.78 NIL 0.7 46
NO yes yes NO YES NO 1+ 4+ 1+ NO NO M1 E0 S1 T1 NO GIVEN 2.2 1 NO No 0.01 NIL 1 70.8
NO NO NO NO NO NO No 1+ NO NO 1+ M1 E1 S1 T0 NO GIVEN 1 2 NO No 0.12 NIL 0.9 62
NO yes yes NO No No No 1+ NO NO 1+ M1 E1 S1 T2 NO GIVEN 2.8 1 NO No 4 NIL 1.8 19
NO NO NO NO YES NO No 1+ NO NO 1+ M0 E1 S1 T1 YES GIVEN 1.9 1 NO No 1.9 NIL 1.5 19
NO yes Yes NO NO NO NO 1+ NO NO NO M1 E1 S1 T1 NO GIVEN 1.2 1 NO No 4.2 NIL 5.6 12
NO YES YES NO NO NO 2+ 4+ NO NO N0 M1 E0 S1 T2 NO GIVEN 2.1 1 NO No 2.48 NIL 1.6 18
NO YES YES NO No No 1+ 1+ NO 1+ 1+ M1 E0 S1 T2 NO GIVEN 1.49 1 NO No 0.8 NIL 1.1 51
NO NO NO NO NO NO 1+ 4+ N0 NO 1+ M1 E1 S0 T1 NO GIVEN 1.1 2 NO No 0.11 NIL 0.8 68.7
NO yes yes NO No NO 2+ 4+ NO NO 1+ M1 E1 S0 T2 YES GIVEN 5.2 1 NO No 0.46 NIL 0.9 62.6
NO NO NO NO YES NO NO 1+ NO NO NO M0 E0 S0 T2 NO GIVEN 1.15 1 NO No 2.7 NIL 1.86 41.9
NO yes yes NO YES No 1+ 4+ NO NO NO M1 E1 S0 T2 YES GIVEN 4.6 1 NO No 1.6 NIL 2.1 14
NO NO NO NO NO NO 1+ 1+ NO NO 1+ M0 E0 S0 T1 NO GIVEN 2.1 1 GIVEN No 1.07 NIL 0.8 80
NO yes yes NO YES NO 1+ 4+ 1+ NO 1+ M0 E1 S1 T1 NO GIVEN 5.1 1 NO No 2.6 NIL 1.6 44.6
YES NO NO NO No No No 1+ NO NO NIL M1 E1 S1 T2 NO GIVEN 2.72 2 NO No 0.8 NIL 1.1 78
YES yes NO NO NO NO 1+ 1+ 1+ NO NIL M0 E1 S0 T2 NO GIVEN 2.27 1 NO No 0.06 NIL 0.8 78.8
YES NO NO NO YES No 2+ 4+ NO NO NIL M0 E1 S1 T1 NO GIVEN 1.2 2 NO No 4.8 NIL 4.2 24
NO yes NO NO No No No 1+ 1+ NO NIL M1 E0 S0 T1 NO NO 1.2 2 NO No 0.2 NIL 0.7 111.4
YES yes NO NO YES No 1+ 1+ NO NO NIL M1 E0 S0 T1 NO GIVEN 2 1 NO No 0.2 NIL 0.8 114.6
NO YES NO NO YES NO 1+ 4+ NO NO 2+ M0 E1 S0 T0 NO NO 0.9 2 NO No NIL NIL 0.8 106
NO yes NO NO YES NO 2+ 4+ NO NO 1+ M0 E1 S1 T2 NO NO 0.8 2 NO No 0.2 4-8 RBC 0.7 91
YES NO NO NO YES No No 1+ NO NO NO M1 E0 S0 T2 NO NO 2.6 2 NO No 1.4 NIL 1.4 62.7
NO NO NO NO YES NO 2+ 4+ NO NO 1+ M1 E1 S1 T2 NO GIVEN 1.8 2 NO No 0.28 NIL 1.2 54.1
YES NO NO NO YES No No 4+ 1+ NO NO M1 E1 S1 T1 NO GIVEN 4.8 1 NO No 2 NIL 5.2 18.6
YES yes NO NO No No No 4+ 1+ NO NO M0 E1 S0 T1 NO GIVEN 1 2 NO No 0.2 NIL 0.8 92.6
YES yes NO NO YES No NO 1+ NO NO NO M1 E1 S0 T1 NO GIVEN 1 1 NO No 1.6 NIL 1.6 46
YES NO NO NO YES No 1+ 1+ 1+ NO NO M0 E0 S0 T0 NO GIVEN 1.8 2 NO No 0.04 NIL 1 81.4
NO NO NO YES No No 1+ 4+ NO NO NO M0 E0 S0 T0 NO NO 2.1 2 NO No NIL NIL 0.6 74.9
YES NO NO NO No No 2+ 1+ 1+ NO 1+ M1 E1 S1 T2 PARTIAL GIVEN 1.72 1 NO No 0.8 NIL 0.8 84.1
NO YES NO YES NO NO 1+ 4+ NO NO NO M1 E1 S0 T2 NO NO 2.1 2 NO No NIL NIL 0.6 108
NO yes NO YES NO NO NO 4+ 1+ NO NO M1 E0 S0 T2 NO NO 2.8 2 NO No 0.04 NIL 0.8 70.4
YES yes NO NO No No 1+ 1+ NO NO 2+ M1 E1 S0 T1 NO GIVEN 2.1 1 NO No 0.8 NIL 0.7 79
YES yes NO NO NO NO 1+ 1+ 1+ NO 1+ M1 E0 S1 T2 NO NO 1.1 2 NO No 0.14 NIL 0.9 68
YES NO NO NO YES No No 1+ NO NO 1+ M1 E0 S0 T1 NO NO 2.1 2 NO No 0.2 NIL 1.1 61
YES NO NO NO YES NO 2+ 1+ NO NO 1+ M1 E0 S1 T1 NO NO 2.8 1 NO No 0.06 NIL 0.8 82.5
YES Yes NO NO No No No 4+ NO NO NO M0 E0 S0 T0 NO NO 1.2 2 NO No 1.2 NIL 1 70
YES yes NO NO YES NO 2+ 4+ NO NO 1+ M0 E0 S1 T0 NO NO 1.4 2 NO No 1.4 NIL 1.1 92.8
YES yes NO NO YES No No 1+ NO NO NO M1 E0 S1 T2 NO NO 2.8 1 NO No 0.2 NIL 0.8 60
YES yes NO NO No No 2+ 4+ 1+ 1+ 1+ M1 E0 S0 T2 NO NO 1.6 1 NO No 0.02 NIL 0.9 67
YES NO NO NO No No No 1+ NO NO NO M1 E0 S0 T2 NO GIVEN 1.4 2 NO No 0.8 NIL 1 85.8
NO yes NO NO NO NO 1+ 4+ NO NO NO M0 E0 S1 T0 NO NO 1.8 2 GIVEN No 0.06 NIL 0.9 70.8
YES NO NO NO No NO No 1+ 1+ 1+ 1+ M1 E0 S1 T1 N0 GIVEN 2.1 1 NO No 0.26 NIL 0.9 67.8
NO YES NO NO YES NO NO 1+ 1+ NO 1+ M1 E0 S1 T2 NO GIVEN 1.1 1 NO No 0.02 NIL 0.8 94.7
NO yes NO NO YES No 1+ 4+ NO NO N0 M1 E0 S1 T2 NO GIVEN 2.1 1 NO No 0.06 NIL 1 74
YES YES NO NO YES 2 1+ 1+ 2+ 1+ 1+ M1 E0 S0 T2 NO NO 2.1 1 NO No 0.06 NIL 1.2 62
YES YES NO NO NO 2 1+ 4+ 1+ 1+ NO M1 E0 S0 T1 N0 GIVEN 2.6 1 NO No 0.06 NIL 1 77
YES YES NO NO NO NO 1+ 2+ NO NO NO M1 E0 S0 T1 NO GIVEN 2.1 2 NO No 0.4 NIL 0.8 110.9
 
 
 
 FIGURE 1:SEX RATIO 
           
FIGURE 2: SYNDROMIC PRESENTATION OF IgA (IN PERCENTAGE) 
 
FIGURE 3: BIOPSY FINDING IN IgAN(MEST SCORING) IN PERCENTAGE: 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4: VARIABLES ANALYSED IN PATIENTS PRESENTED WITH RENAL FAILURE: 
 
 
  
 
 
 
FIGURE 5.VARIABLES ANALYSED  IN PROGRSESSION TO CKD 
 
 
 
 
 
 
Name:                                                                          Sex:                                  Age: 
I P No:                                                                         Address: 
DOA: 
                                                               
PRESENTATION  DURATION
1.Hematuria(Micro/Macro) 
2.Edema legs 
3.Oliguria/Anuria 
4.Hypertension 
5.AKI 
6.CKD(Duration of renal failure)
7.Duration of follow up 
8.Family h/o 
 
      
 
INVESTIGATION    RESP TO Rx
URINE     
PROTEIN     
RBC     
DEPOSITS     
PCR     
C/S     
Hb     
Tc     
PLATELETS     
UREA     
CREATININE     
SUGAR     
URIC ACID     
T.PROTEIN     
ALBUMIN     
BILIRUBIN     
OT     
PT     
ALP     
C3/C4     
Na/K/     
USG ABD     
              
                          
Biopsy findings: 
        LM: 
 
        IF: 
 
       MEST SCORE  
 
     
  TREATMENT 
DRUGS  DOSE DURATION 
ACEI/ARB/STATIN 
STEROIDS 
CYCLOPHOSPHAMIDE 
MMF 
AZATHIOPRINE 
 

